Full Length Article| Volume 155, P23-27, July 2017

Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study


      • ‘Early switchers’ received rivaroxaban after prolonged parenteral/VKA therapy.
      • They had more VTE recurrence risk factors than the rivaroxaban cohort.
      • The crude incidence rates for the primary outcomes reflected this difference.
      • Hospital stay duration was also longer for early switchers.



      XALIA assessed the safety and effectiveness of rivaroxaban for deep vein thrombosis (DVT) treatment in routine clinical practice. This substudy describes the clinical characteristics and outcomes of ‘early switchers’ – patients who received heparin or fondaparinux for >2–14 days and/or a vitamin K antagonist (VKA) for 1–14 days before switching to rivaroxaban.

      Materials and methods

      Patients with DVT (latterly with concomitant pulmonary embolism) received rivaroxaban or standard anticoagulation (initial treatment with heparin or fondaparinux, usually overlapping with and followed by a VKA). Patients administered rivaroxaban alone, or heparin or fondaparinux for ≤48 h pre-enrollment were included in the rivaroxaban cohort. Therapy type, dose, and duration were at the physician's discretion. Primary outcomes were major bleeding, recurrent venous thromboembolism (VTE), and all-cause mortality.


      In 368 early switchers, recurrence or bleeding risk factors were more prevalent versus the rivaroxaban cohort, including creatinine clearance < 50 mL/min (6.5% vs. 3.9%), previous major bleeding (4.6% vs. 1.4%), active cancer (8.2% vs. 5.6%), and concomitant pulmonary embolism (20.9% vs. 8.4%). Crude incidence rates were numerically higher versus the rivaroxaban cohort for major bleeding (1.4% vs. 0.7%), recurrent VTE (2.2% vs. 1.4%), and all-cause mortality (0.8% vs. 0.5%).


      Patients who switched to rivaroxaban early in the treatment process had a higher frequency of risk factors for bleeding and recurrent VTE than patients treated with rivaroxaban; reflected by the higher risk of adverse events in that group during follow-up.


      CNS (central nervous system), DVT (deep vein thrombosis), IQR (interquartile range), PE (pulmonary embolism), Q (quartile), VKA (vitamin K antagonist), VTE (venous thromboembolism)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The EINSTEIN Investigators
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N. Engl. J. Med. 2010; 363: 2499-2510
        • The EINSTEIN–PE Investigators
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N. Engl. J. Med. 2012; 366: 1287-1297
        • Ageno W.
        • Mantovani L.G.
        • Haas S.
        • Kreutz R.
        • Monje D.
        • Schneider J.
        • et al.
        Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
        Lancet Haematol. 2016; 3: e12-e21
        • Agnelli G.
        • Gallus A.
        • Goldhaber S.Z.
        • Haas S.
        • Huisman M.V.
        • Hull R.D.
        • et al.
        Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study.
        Circulation. 2007; 116: 180-187
        • Buller H.R.
        • Lensing A.W.A.
        • Prins M.H.
        • Agnelli G.
        • Cohen A.
        • Gallus A.S.
        • et al.
        A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
        Blood. 2008; 112: 2242-2247
        • Yeh C.H.
        • Gross P.L.
        • Weitz J.I.
        Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
        Blood. 2014; 124: 1020-1028
        • Prins M.H.
        • Lensing A.W.A.
        • Brighton T.A.
        • Lyons R.M.
        • Rehm J.
        • Trajanovic M.
        • et al.
        Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
        Lancet Haematol. 2014; 1: e37-e46
        • Prins M.H.
        • Lensing A.W.A.
        • Bauersachs R.
        • van Bellen B.
        • Bounameaux H.
        • Brighton T.A.
        • et al.
        Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
        Thromb. J. 2013; 11: 21